Replies to post #227051 on Biotech Values

[Whalatane]

MDCO ... great. It’s going to be a Vascepa ( AMRN ) and inclinisran ( soon to be NVS ) world for at least one CAD patient ( me ) ... plus I expect millions more
Great news ... long both
Kiwi

[DewDiligence]

If NVS-MDCO is actually happening, the deal will probably be formally announced in time to hold an investor CC before the market open on Monday.

[DewDiligence]

NVS acquires MDCO for $85/sh cash—a 64% premium to MDCO’s closing price on 11/15/19, the day before serious buyout rumors began circulating:

https://www.globenewswire.com/news-release/2019/11/24/1951667/0/en/Novartis-to-acquire-The-Medicines-Company-for-USD-9-7-bn-adding-inclisiran-a-potentially-transformational-investigational-cholesterol-lowering-therapy-to-address-leading-global-cau.html

https://www.novartis.com/sites/www.novartis.com/files/novartis-mdco-acquisition.pdf (CC slides)

The nominal deal value is $9.7B (on a fully-diluted basis). There is no CVR.